Obstructive jaundice caused by primary duodenal lymphoma. Case report and review of the literature.
Peter
Ulrich
U
Honegger
Hanspeter
H
Koelz
Hans Rudolf
HR
D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D004379:Duodenal Neoplasms / Q000150:complications* / Q000188:drug therapy / Q000532:radiotherapy; D005260:Female; D006801:Humans; D041781:Jaundice, Obstructive / Q000188:drug therapy / Q000209:etiology* / Q000532:radiotherapy; D008223:Lymphoma / Q000150:complications* / Q000188:drug therapy / Q000532:radiotherapy; D011241:Prednisone / Q000627:therapeutic use; D000069283:Rituximab; D014750:Vincristine / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone